Content Hub

Capture

NEWLY ADDED!

CAR-TCR: Article

CAR T: Fireside Chat

Helen Tayton- Martin, CBO, Adaptimmune
André Choulika
, CEO,Cellectis
Michael Koslowski
, CMO, GammaDelta Therapeutics
Dolores Schendel
, CEO, Medigene
Jacob Plieth
, Senior Reporter,Vantage Analysis

Presentations

Capture

NEWLY ADDED!

CAR-TCR Presentation

CAR T: Continuation in a Revolution of Cancer Therapeutics

Dr. Joseph McGuirk, Professor of Medicine Schutte Speas Professor of Hematology Oncology. Medical Director, BMT and Cellular Therapeutics. Division Director, Hematologic Malignancies and Cellular Therapeutics

Capture

NEWLY ADDED!

CAR-TCR Presentation

Overcoming Treatment
Resistance to T Cell
Therapy

Adrian Bot, M.D., Ph.D.
Vice President, Translational Medicine

Capture

NEWLY ADDED!

CAR-TCR Presentation

Navigating Regulatory Requirements for
Early Phase CAR-T Clinical Studies

Elena Spanjaard, Global Head of Regulatory Affairs, Celyad

Capture

NEWLY ADDED!

CAR-TCR Presentation

CAR T Cells for Solid Tumours, To Do List

Francesco M. Marincola, Chief Research Officer, Refuge Biotechnologies

Capture

NEWLY ADDED!

CAR-TCR Presentation

Identification of Novel Shared Targets for Solid Tumors

Hans-Peter Gerber, Ph.D. SVP & CSO,3T Biosciences

Capture

NEWLY ADDED!

CAR-TCR Presentation

Cross-Sector Efforts to Advance Gene & Cell Therapy Manufacturing

Michael Lehmicke, Director, Science & Industry Affairs

Capture

NEWLY ADDED!

CAR-TCR Presentation

The Bridge to Curative Cellular Therapies

Paul Rennert, CAR-TCR Summit 2019

Capture

NEWLY ADDED!

CAR-TCR Presentation

Next generation, contextual regulation of CAR T function in vivo:

Zhifen Yang, Senior Scientist, Refuge Biotechnologies

Magazines

Annotation 2020-02-12 162709

NEWLY ADDED!

CAR-TCR Magazine - Q1

Interviews

Laura Pierce Interview Capture

NEWLY ADDED!

CAR-TCR Conversation with...

Laura Pierce, Biomedical Engineer, NIST

In this conversation, Laura expresses her opinions on the greatest challenges currently facing developers of cell therapies, as well as her thoughts on what the future might hold for CAR-TCR.

Sarah Snykers Capture

NEWLY ADDED!

CAR-TCR Conversation with...

Sarah Snykers, Quality Control Manager, Celyad

In this conversation, Sarah shares her thoughts on the best direction for cell therapy drug developers to take, in order to drive the progression of CAR-TCR treatments.

CAR-TCR Conversation with...

Peter Emtage, Senior Vice President, Head of Cell Therapy Research, Kite, a Gilead Company

In this conversation, Peter shares his views on the clinical and commercial progression of CAR-T therapies after a whirlwind few years.

Capture

CAR-TCR Conversation with...

David Sourdive, Executive Vice President, Technical Operations & Co-founder, Cellectis

In this conversation, David discusses the disruptive genetic engineering approaches developed to create efficacious, next generation CAR and TCR therapies.

Press Releases

Press Release: Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology

Logos

Industry Surveys

CART Industry Survey Snippet

NEWLY ADDED!

 

CAR-TCR Industry Survey Results 2019

Here’s what your peers think about key developments and priorities in this rapidly evolving field.

CAR-TCR-2018-Survey-1

CAR-TCR Industry Survey 2018

The infographic provides some great insights into solid tumor approaches, commercial impact and limitations of manufacturing strategies.